December 19, 2018 / 4:11 AM / 6 months ago

BRIEF-Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology

Dec 18 (Reuters) -

* AMGEN AND MOLECULAR PARTNERS ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY

* AMGEN-AMGEN AND MOLECULAR PARTNERS ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY

* AMGEN-MOLECULAR PARTNERS WILL RECEIVE UPFRONT PAYMENT OF $50 MILLION

* AMGEN-PARTIES WILL SHARE CLINICAL DEVELOPMENT COSTS IN DEFINED PERCENTAGES FOR FIRST THREE INDICATIONS SUBJECT TO CERTAIN CONDITIONS

* AMGEN-FOR ALL ADDITIONAL CLINICAL TRIALS, AMGEN IS RESPONSIBLE FOR ALL DEVELOPMENT COSTS

* AMGEN - MOLECULAR PARTNERS ELIGIBLE TO RECEIVE UP TO $497 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS

* AMGEN - PARTIES WILL JOINTLY EVALUATE MP0310 IN COMBINATION WITH AMGEN’S ONCOLOGY PIPELINE PRODUCTS

* AMGEN-ANTICIPATE MP0310 TO ENTER CLINIC IN 2019 Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below